NeuroRx, Inc.
913 North Market Street
Suite 200
Wilmington
Delaware
19801
United States
Tel: 973-442-1555 ext. 116
Website: http://www.neurorxpharma.com/
69 articles with NeuroRx, Inc.
-
NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation & Behavior (ASIB)
12/27/2017
The collaboration also includes Baylor College of Medicine, in Houston, TX.
-
NeuroRx Awarded FDA Fast Track Designation For First Drug Regimen Targeting Suicide In Bipolar Depression
9/6/2017
-
NeuroRx Partners With Leading Patient Advocacy Groups And Experts In The Bipolar Disorder Community To Launch 1st Global "Voice Of The Patient" Survey To Gain Insights Into Care Received During Hospitalization For A Suicidal Crisis
4/12/2017
-
NeuroRx Announces FDA IND Clearance For NRX-101 Phase 2b/3 Study And Publication Of Promising Biomarker Data
1/4/2017
-
NeuroRx Solidifies Intellectual Property Position - Receives Notice Of Allowance By US Patent Office
10/18/2016
-
NeuroRx Announces Participation At The 18th Annual Rodman & Renshaw Global Investment Conference In New York City September 11-13, 2016
9/7/2016
-
NeuroRx Awarded First Prize In Annual Israel BIOMED Startup Competition
6/1/2016
-
Zomedica Pharmaceuticals Corp. Announces First Quarter 2016 Financial Results Of Zomedica Pharmaceuticals Inc.
5/27/2016
-
NeuroRx Wins Startup Competition At IATI-Biomed 2016, Israel’s Leading Life Science Conference
5/27/2016